{
    "clinical_study": {
        "@rank": "92463", 
        "arm_group": [
            {
                "arm_group_label": "MK-8666 (Dose 1)", 
                "arm_group_type": "Experimental", 
                "description": "MK-8666, Dose 1, oral, once a day (QD) for Days 1 to 14."
            }, 
            {
                "arm_group_label": "MK-8666 (Dose 2)", 
                "arm_group_type": "Experimental", 
                "description": "MK-8666, Dose 2, oral, QD, for Days 1 to 14"
            }, 
            {
                "arm_group_label": "MK-8666 (Dose 3)", 
                "arm_group_type": "Experimental", 
                "description": "MK-8666, Dose 3, oral, QD for Days 1 to 14"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo corresponding to MK-8666 doses, oral, QD for Days 1 to 14"
            }
        ], 
        "brief_summary": {
            "textblock": "This is a study of the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics\n      (PD) of MK-8666 in participants with type 2 diabetes mellitus (T2DM).  Participants enrolled\n      in this trial would be either treatment-naive or have washed off of oral anti-hyperglycemic\n      agents.  MK-8666 is planned to be administered orally for up to 2 weeks."
        }, 
        "brief_title": "Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of MK-8666 in Participants With Type 2 Diabetes Mellitus (MK-8666-003)", 
        "completion_date": {
            "#text": "April 2014", 
            "@type": "Actual"
        }, 
        "condition": "Type 2 Diabetes Mellitus", 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 2"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  If female, must be either postmenopausal or surgically sterile\n\n          -  A Body Mass Index (BMI) \u226518 kg/m^2 to \u226440 kg/m^2, inclusive.\n\n          -  A diagnosis of T2DM\n\n          -  Drug na\u00efve or is being treated with no more than 2 oral antihyperglycemic agents\n             (thiazolidenediones are excluded)\n\n          -  Judged to be in good health except for T2DM\n\n          -  Willing to follow a standard weight maintaining diet throughout the study\n\n          -  A nonsmoker or has not used nicotine or nicotine-containing products for at least 3\n             months\n\n        Exclusion Criteria:\n\n          -  A history of clinically significant endocrine (except T2DM), gastrointestinal,\n             cardiovascular, hematological, hepatic, immunological, renal, respiratory, or\n             genitourinary abnormalities or diseases\n\n          -  A history of myositis or complaints including diffuse myalgias, muscle tenderness, or\n             weakness.\n\n          -  A history of cancer (malignancy) excepting adequately treated non-melanomatous skin\n             carcinoma or carcinoma in situ of the cervix\n\n          -  Has clinically unstable diabetic retinopathy, neuropathy, and/or clinical evidence of\n             gastroparesis (frequent nausea, bloating or vomiting, severe gastroesophageal reflux,\n             early satiety)\n\n          -  A history of type 1 diabetes mellitus and/or history of ketoacidosis\n\n          -  Taking a medication for a co-morbid condition that is not permitted during the study\n\n          -  A history of significant multiple and/or severe allergies\n\n          -  Positive for hepatitis B surface antigen, hepatitis C antibodies or human\n             immunodeficiency virus\n\n          -  Had major surgery, donated or lost 1 unit of blood within 4 weeks prior to study\n             participation\n\n          -  Participated in another investigational trial within 4 weeks prior to study\n             participation\n\n          -  Consumes excessive amounts of alcoholic or caffeine-containing beverages\n\n          -  A regular user of illicit drugs or a history of drug or alcohol abuse within the past\n             year"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "63", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "October 14, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01971554", 
            "org_study_id": "8666-003"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "MK-8666 (Dose 1)", 
                    "MK-8666 (Dose 2)", 
                    "MK-8666 (Dose 3)"
                ], 
                "description": "MK-8666, capsules, oral, QD, Days 1 to 14", 
                "intervention_name": "MK-8666", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "MK-8666 (Dose 1)", 
                    "MK-8666 (Dose 2)", 
                    "MK-8666 (Dose 3)", 
                    "Placebo"
                ], 
                "description": "Placebo, capsules, oral, QD, Days 1 to 14", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "May 7, 2014", 
        "number_of_arms": "4", 
        "official_title": "A Multiple Dose Clinical Trial to Study the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of MK-8666 in Type 2 Diabetes Mellitus Patients", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "April 2014", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "Change from Baseline in Fasting Plasma Glucose", 
                "safety_issue": "No", 
                "time_frame": "Baseline and Day 14"
            }, 
            {
                "measure": "Percentage of Participants Who Experienced an Adverse Event (AE)", 
                "safety_issue": "Yes", 
                "time_frame": "Up to Day 29"
            }, 
            {
                "measure": "Percentage of Participants Who Discontinued Study Treatment Due to an AE", 
                "safety_issue": "Yes", 
                "time_frame": "Up to Day 14"
            }
        ], 
        "removed_countries": {
            "country": "United States"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01971554"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Area Under the Plasma Concentration-Time Curve from Time Zero to 24 Hours (AUC0-24h)", 
                "safety_issue": "No", 
                "time_frame": "Day 1 and Day 14"
            }, 
            {
                "measure": "Maximum Plasma Drug Concentration After Dosing (Cmax)", 
                "safety_issue": "No", 
                "time_frame": "Day 1 and Day 14"
            }, 
            {
                "measure": "Time to Reach Cmax (Tmax)", 
                "safety_issue": "No", 
                "time_frame": "Day 1 and Day 14"
            }
        ], 
        "source": "Merck Sharp & Dohme Corp.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Merck Sharp & Dohme Corp.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}